1
|
Polidori P, Makridaki D, Kohl S. Clinical trials. Eur J Hosp Pharm 2024; 31:162-164. [PMID: 36931719 PMCID: PMC10895182 DOI: 10.1136/ejhpharm-2022-003471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/19/2023] Open
Affiliation(s)
- Piera Polidori
- Hospital Pharmacy Complex Operational Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy
| | - Despina Makridaki
- Pharmacy Services, "Sismanoglio- Amalia Fleming", General Hospital of Attica, Athens, Greece
| | - Stephanie Kohl
- Policy & Advocacy, European Association of Hospital Pharmacists, Brussels, Belgium
| |
Collapse
|
2
|
Miljković N, Polidori P, Leonardi Vinci D, Kuruc Poje D, Makridaki D, Kohl S, Süle A. Results of EAHP's 2023 shortages survey. Eur J Hosp Pharm 2024:ejhpharm-2024-004090. [PMID: 38307707 DOI: 10.1136/ejhpharm-2024-004090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2024] [Accepted: 01/23/2024] [Indexed: 02/04/2024] Open
Abstract
AIMS AND OBJECTIVE The aim of the European Association of Hospital Pharmacists (EAHP)'s 2023 shortages survey was to collect data on causes and mitigation strategies of shortages of medicines and medical devices and their impact on patient care. The survey targeted hospital pharmacists (HPs), physicians (PHYs), nurses (NRS) and other healthcare professionals (OHCPs). A separate set of questions addressed patients (PTNs). METHODS A 49-question survey was carried out by a team at EAHP, collecting information from European HPs, PTNs, NRS, PHYs and OTHCs on shortages of medicines and medical devices in their respective countries. The survey ran from 27 February to 19 May 2023. The results were analysed by EAHP. RESULTS There were 1497 HP responses to the 2023 survey. While 95% (n=1429) of HPs and 86% (n=127) of OHCPs consider medicine shortages an ongoing problem, 84% (n=48) of PHYs and 68% (n=15) of NRS also agreed. Shortages of active pharmaceutical ingredients (77%, n=1148), manufacturing (67%, n=1007) and supply chain problems (50%, n=752) are major causes of shortages according to HPs as well as NRS and OHCPs; PHYs (49%, n=18) consider pricing to be the driver. More than 60% (n=765) of HPs, 55% (n=11) of NRS, 57% (n=30) of PHYs and 46% (n=56) of OHCPs experienced shortages of medical devices in 2022. Antimicrobials were most affected, according to all respondent groups, followed by analgesics, anaesthetics, cardiovascular and paediatric medicines. HPs (59%, n=269), NRS (57%, n=4), OHCPs (56%, n=37) and PHYs (54%, n=14) consider delays in care as the main consequence of medication shortages. CONCLUSIONS Shortages of medicines and medical devices affect healthcare services and patient care. Increased transparency and access to information regarding ongoing and emerging shortages as well as better preparedness of healthcare professionals is crucial to their effective management.
Collapse
Affiliation(s)
- Nenad Miljković
- Hospital Pharmacy, Institute of Orthopaedics Banjica, Belgrade, Serbia
- European Association of Hospital Pharmacists, Brussels, Belgium
| | - Piera Polidori
- Hospital Pharmacy, The joined hospitals Villa Sofia-Cervello, Palermo, Italy
| | | | - Darija Kuruc Poje
- Hospital Pharmacy, General Hospital "Dr Tomislav Bardek", Koprivnica, Croatia
| | - Despina Makridaki
- Pharmacy Services, "Sismanoglio- Amalia Fleming", General Hospital of Attica, Athens, Greece
| | - Stephanie Kohl
- Policy and Advocacy, European Association of Hospital Pharmacists, Brussels, Belgium
| | - András Süle
- European Association of Hospital Pharmacists, Brussels, Belgium
- Hospital Pharmacy, Péterfy Hospital, Budapest, Hungary
| |
Collapse
|
3
|
Lozano-Blázquez A, Makridaki D, Plesan CR, Kohl S. Advanced therapy medicinal products. Eur J Hosp Pharm 2023; 31:63-65. [PMID: 36931720 PMCID: PMC10800277 DOI: 10.1136/ejhpharm-2022-003470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/19/2023] Open
Affiliation(s)
- Ana Lozano-Blázquez
- Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Despina Makridaki
- Pharmacy Services, "Sismanoglio- Amalia Fleming", General Hospital of Attica, Athens, Greece
| | | | - Stephanie Kohl
- Policy & Advocacy, European Association of Hospital Pharmacists, Brussels, Belgium
| |
Collapse
|
4
|
Horák P, Makridaki D, Polidori P, Süle A, Bertin L, Kohl S. Hospital pharmacy workforce. Eur J Hosp Pharm 2023:ejhpharm-2023-003919. [PMID: 37696590 DOI: 10.1136/ejhpharm-2023-003919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/13/2023] Open
Affiliation(s)
- Petr Horák
- Hospital Pharmacy, University Hospital Motol, Prague, Czech Republic
| | - Despina Makridaki
- Pharmacy Services, "Sismanoglio- Amalia Fleming", General Hospital of Attica, Athens, Greece
| | - Piera Polidori
- Hospital Pharmacy Complex Operational Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy
| | - András Süle
- Department of Pharmacy, Peterfy Korhaz-Rendelointezet es Manninger Jeno Orszagos Traumatologiai Intezet, Budapest, Hungary
- European Association of Hospital Pharmacists, Brussels, Belgium
| | - Louis Bertin
- Hospital Pharmacy Complex, Centre Hospitalier de l'Arrondissement de Montreuil/mer, Montreuil/mer, France
| | - Stephanie Kohl
- Policy & Advocacy, European Association of Hospital Pharmacists, Brussels, Belgium
| |
Collapse
|
5
|
Miljković N, Makridaki D, Kohl S. Access to medicines. Eur J Hosp Pharm 2023; 30:257-260. [PMID: 34949652 PMCID: PMC10447961 DOI: 10.1136/ejhpharm-2021-002974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
- Nenad Miljković
- Hospital Pharmacy, Institute of Orthopaedic Surgery "Banjica", Belgrade, Serbia
| | - Despina Makridaki
- Pharmacy Services, Sismanoglio-Amalia Fleming, General Hospital of Attica, Athens, Greece
| | - Stephanie Kohl
- Policy & Advocacy, European Association of Hospital Pharmacists, Brussels, Belgium
| |
Collapse
|
6
|
Batista A, Makridaki D, van der Schors T, Kohl S. Hazardous medicinal products. Eur J Hosp Pharm 2023; 30:261-263. [PMID: 36922005 PMCID: PMC10447955 DOI: 10.1136/ejhpharm-2022-003472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/17/2023] Open
Affiliation(s)
- Aida Batista
- Pharmacy, Centro Hospitalar do Médio Ave EPE, Santo Tirso, Portugal
| | - Despina Makridaki
- Pharmacy Services, "Sismanoglio- Amalia Fleming", General Hospital of Attica, Athens, Greece
| | | | - Stephanie Kohl
- Policy & Advocacy, European Association of Hospital Pharmacists, Brussels, Belgium
| |
Collapse
|
7
|
Affiliation(s)
- András Süle
- Department of Pharmacy, Péterfy Hospital - National Institute of Traumatology, Budapest, Hungary
| | - Petr Horák
- Hospital Pharmacy, Motol University Hospital, Prague, Czech Republic
| | - Despina Makridaki
- Pharmacy, 'Sismanoglio- Amalia Fleming', General Hospital of Attica, Athens, Greece
| | - Stephanie Kohl
- Policy & Advocacy, European Association of Hospital Pharmacists, Brussels, Belgium
| |
Collapse
|
8
|
Leonardi Vinci D, Polidori P, Miljković N, Batista A, Amann S, Makridaki D, Kohl S. Lessons learnt from the COVID-19 pandemic: results of EAHP survey on the future crisis preparedness of hospital pharmacies. Eur J Hosp Pharm 2021; 29:242-247. [PMID: 34497129 PMCID: PMC8440123 DOI: 10.1136/ejhpharm-2021-002944] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Accepted: 08/03/2021] [Indexed: 12/22/2022] Open
Abstract
Aim The present survey aimed to collect information on the lessons learnt from the COVID-19 pandemic by hospital pharmacists. It focused on the shortages of health goods and the experiences of hospitals during the first phase of the crisis. Methods A 17-question survey was conducted by EAHP, looking at the experiences of hospital pharmacists during the COVD-19 pandemic. The survey ran from 16 September to 23 December 2020. Statistical analysis included backward stepwise logistic regression (BSLR), Pearson’s χ2 test, t-test and one-way ANOVA, as appropriate; p≤0.05 was considered statistically significant. Results 1466 hospital pharmacists answered the survey fully. 58%, 63% and 69% of them experienced shortages in medicines, disinfectants and personal protective equipment (PPE), respectively. BSLR showed that being a COVID-19 dedicated hospital increased the risk of medicine shortages (OR 1.63, 95% CI 1.15 to 2.31) but the shortages of disinfectants and PPE were lower (OR 0.62, 95% CI 0.44 to 0.88; OR 0.60, 95% CI 0.42 to 0.85). Being a specialised hospital reduced the odds of medicine shortages (OR 0.59, 95% CI 0.40 to 0.88), while countries with a greater percentage of the population infected had increased odds for all three types of shortages (OR 1.16, 95% CI 1.01 to 1.23; OR 1.34, 95% CI 1.19 to 1.50; OR 1.21, 95% CI 1.09 to 1.35). The odds were also higher in answers submitted in September compared with December. The classes of medicines with highest reported shortages were anaesthetics, antibiotics and muscle relaxants. The main entities that provided support were the national competent authorities and manufacturers. Conclusion Medicine shortages affected the work of hospital pharmacists during the early stages of the pandemic. The features of the crisis and the feedback described in this survey can provide interesting insights for a more resilient healthcare framework in the future.
Collapse
Affiliation(s)
| | - Piera Polidori
- Clinical Pharmacy, Institute Mediterranean per i Trapianti e Terapie ad Alta Specializzazione, Hospital Pharmacy Via Ernesto Tricomi, Palermo, Italy
| | - Nenad Miljković
- Hospital Pharmacy, Institute of Orthopaedics Banjica, Hospital Pharmacy, Belgrade, Serbia
| | - Aida Batista
- Pharmacy, Centro Hospitalar Vila Nova de Gaia/Espinho, EPE, Vila Nova de Gaia, Portugal
| | - Steffen Amann
- Krankenhausapotheke (Hospital Pharmacy), Muenchen Klinik gGmbH, Munchen, Germany
| | - Despina Makridaki
- Pharmacy Services, "Sismanoglio- Amalia Fleming", General Hospital of Attica, Athens, Greece
| | - Stephanie Kohl
- European Association of Hospital Pharmacists, 1200 Brussels, Belgium
| |
Collapse
|
9
|
Leonardi Vinci D, Meccio A, Provenzani A, Faggiano ME, Miljković N, Makridaki D, Horák P, Polidori P. The European COVID-19 drugs calculation tool: an aid for the estimation of the drugs needed during the SARS-CoV 2 pandemic. Eur J Hosp Pharm 2021; 29:e23-e29. [PMID: 33619027 PMCID: PMC7902324 DOI: 10.1136/ejhpharm-2020-002633] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2020] [Revised: 01/19/2021] [Accepted: 02/02/2021] [Indexed: 01/08/2023] Open
Abstract
Objective To create an informatics supportive tool, which can assist healthcare professionals in estimating potential requirements for essential drug supplies to respond to the current SARS-CoV-2 pandemic based on epidemiological forecasting. Methods The tool was based on a Susceptible-Infected-Removed (SIR) epidemiological model in which the population is divided into three compartments and transmission parameters are specified to define the rate at which people move between stages. Appropriate data entry was guaranteed by the creation of structured guided paths. The drugs needed for the forecasted patients were estimated according to a list of critical care drugs compiled by consulting previous published scientific works, national and international guidelines. For each drug, an estimation was made of the percentage average ICU uptake for each therapeutic group and active principle. Results The tool consists of a Microsoft Excel template that is based on the initial epidemiological situation, the non-pharmaceutical interventions applied, the risk of hospitalisation based on the population age distribution, and the hospital beds available. The tool provides a forecast of which patients with COVID-19 will need to be treated in a hospital setting. The number of patients is used to estimate the drugs needed based on the average daily dose and the treatment length of each drug. The possibility of editing the type of distribution (exponential or linear) of the number of patients at the beginning of the analysis, the percentage adherence with non-pharmaceutical interventions and their delayed effect, and all the key epidemiological parameters make the estimation tailorable to different clinical contexts and needs. Conclusions This model might be an effective supporting tool that could be easily implemented within the workflow of health professionals. All the information reported in this paper could be useful in developing new strategies to tackle the COVID-19 pandemic.
Collapse
Affiliation(s)
- Daniele Leonardi Vinci
- School of Specialization in Hospital Pharmacy, University of Palermo, Palermo, Sicilia, Italy
| | - Adriano Meccio
- Chemical Engineering, University of Palermo, Palermo, Sicilia, Italy
| | | | | | - Nenad Miljković
- Hospital Pharmacy, Institute of Orthopaedic Surgery "Banjica", Belgrade, Serbia
| | - Despina Makridaki
- Pharmacy Services, "Sismanoglio- Amalia Fleming", General Hospital of Attica, Athens, Greece
| | - Petr Horák
- Hospital Pharmacy, Motol University Hospital, Praha, Praha, Czech Republic
| | | |
Collapse
|
10
|
Moss RJ, Batista A, Makridaki D, Süle A, Kohl S. Procurement. Eur J Hosp Pharm 2019; 26:173-174. [DOI: 10.1136/ejhpharm-2018-001822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Revised: 02/06/2019] [Accepted: 02/12/2019] [Indexed: 11/04/2022] Open
|
11
|
Bochenek T, Abilova V, Alkan A, Asanin B, de Miguel Beriain I, Besovic Z, Vella Bonanno P, Bucsics A, Davidescu M, De Weerdt E, Duborija-Kovacevic N, Fürst J, Gaga M, Gailīte E, Gulbinovič J, Gürpınar EU, Hankó B, Hargaden V, Hotvedt TA, Hoxha I, Huys I, Inotai A, Jakupi A, Jenzer H, Joppi R, Laius O, Lenormand MC, Makridaki D, Malaj A, Margus K, Marković-Peković V, Miljković N, de Miranda JL, Primožič S, Rajinac D, Schwartz DG, Šebesta R, Simoens S, Slaby J, Sović-Brkičić L, Tesar T, Tzimis L, Warmińska E, Godman B. Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. Front Pharmacol 2018; 8:942. [PMID: 29403372 PMCID: PMC5779072 DOI: 10.3389/fphar.2017.00942] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2017] [Accepted: 12/11/2017] [Indexed: 11/23/2022] Open
Abstract
Drug shortages have been identified as a public health problem in an increasing number of countries. This can negatively impact on the quality and efficiency of patient care, as well as contribute to increases in the cost of treatment and the workload of health care providers. Shortages also raise ethical and political issues. The scientific evidence on drug shortages is still scarce, but many lessons can be drawn from cross-country analyses. The objective of this study was to characterize, compare, and evaluate the current systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages within health care systems across a range of European and Western Asian countries. The study design was retrospective, cross-sectional, descriptive, and observational. Information was gathered through a survey distributed among senior personnel from ministries of health, state medicines agencies, local health authorities, other health or pharmaceutical pricing and reimbursement authorities, health insurance companies and academic institutions, with knowledge of the pharmaceutical markets in the 28 countries studied. Our study found that formal definitions of drug shortages currently exist in only a few countries. The characteristics of drug shortages, including their assortment, duration, frequency, and dynamics, were found to be variable and sometimes difficult to assess. Numerous information hubs were identified. Providing public access to information on drug shortages to the maximum possible extent is a prerequisite for performing more advanced studies on the problem and identifying solutions. Imposing public service obligations, providing the formal possibility to prescribe unlicensed medicines, and temporary bans on parallel exports are widespread measures. A positive finding of our study was the identification of numerous bottom-up initiatives and organizational frameworks aimed at preventing or mitigating drug shortages. The experiences and lessons drawn from these initiatives should be carefully evaluated, monitored, and presented to a wider international audience for careful appraisal. To be able to find solutions to the problem of drug shortages, there is an urgent need to develop a set of agreed definitions for drug shortages, as well as methodologies for their evaluation and monitoring. This is being progressed.
Collapse
Affiliation(s)
- Tomasz Bochenek
- Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland
| | - Vafa Abilova
- Analytical Expertise Centre, Ministry of Health, Baku, Azerbaijan
| | - Ali Alkan
- Turkish Medicines and Medical Devices Agency, Ankara, Turkey
| | - Bogdan Asanin
- Department of Surgery, Department of Medical Ethics, Medical Faculty of the University of Montenegro, Podgorica, Montenegro
| | | | - Zeljka Besovic
- Montenegrin Agency for Drugs and Medical Devices, Sector for Drugs and Medical Devices, Podgorica, Montenegro
| | - Patricia Vella Bonanno
- Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom
| | - Anna Bucsics
- Mechanism of Coordinated Access to Orphan Medicinal Products, Brussels, Belgium
| | | | - Elfi De Weerdt
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
| | - Natasa Duborija-Kovacevic
- Department of Pharmacology and Clinical Pharmacology, Medical Faculty of the University of Montenegro, Podgorica, Montenegro
| | - Jurij Fürst
- Department of Medicines, Health Insurance Institute, Ljubljana, Slovenia
| | - Mina Gaga
- 7th Respiratory Medicine Department, Athens Chest Hospital Sotiria, Athens, Greece
| | | | - Jolanta Gulbinovič
- Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University, Vilnius, Lithuania.,State Medicine Control Agency, Vilnius, Lithuania
| | - Emre U Gürpınar
- Turkish Medicines and Medical Devices Agency, Ankara, Turkey
| | - Balázs Hankó
- University Pharmacy Department of Pharmacy Administration, Semmelweis University, Budapest, Hungary
| | - Vincent Hargaden
- School of Mechanical and Materials Engineering, University College Dublin, Dublin, Ireland
| | | | - Iris Hoxha
- Department of Pharmacy, University of Medicine, Tirana, Albania
| | - Isabelle Huys
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
| | - Andras Inotai
- Syreon Research Institute, Budapest, Hungary.,Department of Health Policy and Health Economics, Institute of Economics, Eötvös Loránd University, Budapest, Hungary
| | - Arianit Jakupi
- Department of Drug Management, Faculty of Pharmacy, UBT (Kosovo), Prishtina, Albania
| | - Helena Jenzer
- Health Department, Bern University of Applied Sciences, Bern, Switzerland.,University Hospital of Psychiatry Zurich (PUK), Zurich, Switzerland
| | - Roberta Joppi
- Local Health Unit of Verona-Veneto Region, Verona, Italy
| | - Ott Laius
- State Agency of Medicines, Tartu, Estonia
| | | | - Despina Makridaki
- Panhellenic Association of Hospital Pharmacists, Athens, Greece.,National Organization for Medicines, Athens, Greece
| | - Admir Malaj
- Department of Pharmacy, University of Medicine, Tirana, Albania
| | - Kertu Margus
- Estonian State Agency of Medicines, Tartu, Estonia
| | - Vanda Marković-Peković
- Ministry of Health and Social Welfare, Banja Luka, Republic of Srpska, Bosnia and Herzegovina.,Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka (Republic of Srpska), Banja Luka, Bosnia and Herzegovina
| | | | - João L de Miranda
- Escola Superior de Tecnologia e Gestão, Instituto Politécnico de Portalegre, Portalegre, Portugal.,Centro de Recursos Naturais e Ambiente, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal
| | - Stanislav Primožič
- Agency for Medicinal Products and Medicinal Devices, Ljubljana, Slovenia
| | | | - David G Schwartz
- Graduate School of Business Administration, Bar-Ilan University, Ramat-Gan, Israel
| | | | - Steven Simoens
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
| | - Juraj Slaby
- State Institute for Drug Control, Prague, Czechia
| | | | - Tomas Tesar
- Department of Organisation and Management in Pharmacy, Pharmaceutical Faculty, Comenius University, Bratislava, Slovakia
| | | | - Ewa Warmińska
- Dentons Europe Dąbrowski i Wspólnicy sp. k., Warszawa, Poland
| | - Brian Godman
- Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.,Division of Clinical Pharmacology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.,Health Economics Centre, Liverpool University Management School, Liverpool, United Kingdom
| |
Collapse
|
12
|
Tsiantou V, Mylona K, Karampli E, Boubouchairopoulou N, Kyriopoulos II, Athanasakis K, Gabriel E, Makridaki D, Kyriopoulos J. Access To Orphan Drugs In Greece During Economic Crisis. Value Health 2014; 17:A541. [PMID: 27201742 DOI: 10.1016/j.jval.2014.08.1740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- V Tsiantou
- National School of Public Health, Athens, Greece
| | - K Mylona
- National School of Public Health, Athens, Greece
| | - E Karampli
- National School of Public Health, Athens, Greece
| | | | | | | | - E Gabriel
- Institute of Pharmaceutical Research and Technology, Pallini, Greece
| | - D Makridaki
- Panhellenic Association of Hospital Pharmacists, Marousi, Greece
| | | |
Collapse
|
13
|
Makridaki D, Allagianni C, Skountzou R, Petrogonas M, Rinaki E, Tzimis L. DSL-002 A Pharmacoeconomic Comparison Between a County Hospital in Chania and a Central Hospital in Athens, Greece. Eur J Hosp Pharm 2013. [DOI: 10.1136/ejhpharm-2013-000276.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
14
|
Aravantinos G, Linardou H, Makridaki D, Laiou E, Zafiropoulos A, Janninis J, Sofos G, Gikas D, Samantas E, Markantoni-Kyroudi S. Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study. J BUON 2003; 8:127-32. [PMID: 17472238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
PURPOSE Recombinant human erythropoietin (rHuEPO) represents an attractive alternative to red blood cell (RBC) transfusions for the treatment of chemotherapy-induced anaemia. This prospective, controlled study evaluated the safety and efficacy of rHuEPO in reducing RBC transfusion requirements in patients receiving platinum-based chemotherapy. PATIENTS AND METHODS Patients with histologically proven malignancies, haemoglobin (Hb) values <10.5 g/dl, and receiving platinum-based chemotherapy were randomised to either 150 IU/kg of rHuEPO subcutaneously (s.c.) x3/week (group A), or simple follow-up plus RBC transfusions upon indication (group B). All patients received 200mg of elementary iron (Fe) daily. RESULTS A total of 47 patients were randomised to either group A (n=24) or the control group B (n=23). There was a statistically significant increase of Hb (p <0.0002) and haematocrit (Ht) (p <0.002) in group A patients compared to the control group B. The levels of Hb in group A patients increased significantly with each chemotherapy cycle number. There was a statistically significant (p <0.04) difference in the number of transfusions between the two groups, with only 37.5% of group A patients requiring a RBC transfusion at any time during the study, compared to all patients (100%) in group B. CONCLUSIONS Administration of rHuEPO is an effective intervention for the management of chemotherapy-induced anaemia, significantly reducing RBC transfusion requirements in patients receiving platinum-based chemotherapy. Hb and Ht levels proved reliable indicators for response to rHuEPO treatment.
Collapse
Affiliation(s)
- G Aravantinos
- 3rd Department of Medical Oncology, "Agii Anargiri" Cancer Hospital, Athens, Greece
| | | | | | | | | | | | | | | | | | | |
Collapse
|